阿普罗西坦:第一个内分泌素受体对手对抗抗性高血压
Timothy Nguyen1, Hui Lin2, Diana Tint3
1Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY.
American journal of therapeutics
|July 10, 2025
概括
在耐性高血压患者中,阿普罗西坦有效降低血压. 这种新型内甲素受体抗剂证明了持续的疗效,为难以管理的高血压提供了新的治疗选择.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 临床试验 临床试验
背景情况:
- 耐性高血压影响的个体,尽管最佳治疗至少有三种不同的抗高血压药物,但其血压仍然无法控制.
- 艾普罗西坦是一种新型的双内甲素受体对抗剂 (ETa和ETb),于2024年初被批准用于治疗现有疗法控制不充分的高血压.
研究的目的:
- 评估阿普罗西坦在耐药高血压的成年患者中的疗效和安全性.
- 在一个大型的多中心研究中,与安慰剂相比,评估阿普罗西坦的降血压效果.
主要方法:
- 一项第三阶段的多中心研究随机选择了730名血压≥140毫米的成年患者,同时接受安慰剂或阿布罗西坦 (12.5毫克或25毫克) 以及他们现有的抗高血压药物.
- 患者接受了安慰剂的试验期,并在整个研究期间继续标准背景治疗.
主要成果:
- 在第4周,阿普罗西坦12.5毫克在降低静坐系统血压方面表现出比安慰剂优越的优势.
- 阿普罗西坦的降血压效果持续,在40周观察到统计学上显著的结果,当时25毫克的患者被重新随机分配到安慰剂中.
结论:
- 阿普罗西坦是一种新型内甲素受体抗剂,为耐高血压患者提供了新的治疗选择.
- 该药物在降低血压方面表现出持续的有效性,解决了难以控制的高血压管理的关键未满足需求.
更多相关视频
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
227
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
227
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
931
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
931
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
893
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
893
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
258
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
258
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
516
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
516
01:25Antihypertensive Drugs: Direct Renin Inhibitors
835
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
835